<p>，/PRNewswire/ -- 第 61 届欧洲糖尿病研究协会年会（EASD 2025）在奥地利维也纳成功举行。在会议期间，三诺生物举办了国际行业研讨会和专属的网络晚宴，充分展示了公司在糖尿病管理方面的专业知识。</p>
<p><strong>国际专家赞扬 iCan CGM 的卓越临床表现</strong></p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>洛里·拉费尔教授</p>
<p>在 EASD 2025 开幕的周一，洛里·拉费尔教授、吉多·弗雷克曼博士和朱莉亚·马德尔教授受邀分享与 iCanTM CGM 合作的研究。研讨会强调了 “表现、实用性和儿科” 这几个关键主题，并展示了来自德国和美国的成人及儿童人群的最新研究数据。此外，会议还提供了在实际环境中启动 CGM 系统的见解，展示了来自领先儿科糖尿病中心的专业知识。讨论还探讨了糖尿病技术对热爱飞行的糖尿病患者的旅行和就业机会的潜在影响。</p>
<p><strong>iCan i6 CGM 全球发布：更智能的监测，提升的体验</strong></p>
<p>下一代 iCan i6 CGM 系统成为三诺生物展位的焦点。除了 15 天的准确性和舒适的佩戴体验，iCan i6 还提供多项用户体验升级：一步应用，配备更小、更轻的传感器；支持 27 种语言，全球可及性；内置高度补偿算法，确保高海拔地区的可靠读数；增强的移动应用集成，实现 “轻松监测和全球可及” 的体验。</p>
<p>与此同时，三诺生物的独家合作伙伴 A.Menarini Diagnostics s.r.l 在 EASD 展示了联合品牌的 GlucoMen® iCan CGM 系统。Menarini 通过沉浸式展位体验强调了 iCan 系统的最新功能和临床益处，吸引了现场医疗专业人士的强烈兴趣和参与。</p>
<p><strong>从预防到管理：构建闭环糖尿病生态系统</strong></p>
<p>9 月 15 日，三诺生物举办了一场私人晚宴研讨会，向关键合作伙伴揭示其新的 “A+C” 糖尿病预防与控制生态系统。该模型将 AGEscan 非侵入性筛查与 CGM 结合，以实现早期风险检测和精准干预。三诺生物还介绍了其医院血糖管理解决方案，能够无缝连接门诊和住院场景，实现端到端的数字糖尿病管理，提高效率和护理质量。</p>
<p>从前沿的 CGM 临床研究到综合的预防和医院管理解决方案，三诺生物在 EASD 2025 的参与加强了与专家和合作伙伴的全球合作，展示了其技术创新与患者和临床需求的深度融合。</p>
<p>来源：长沙三诺生物股份有限公司</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDE1Jk5ld3NJdGVtSWQ9Q045ODM1MiZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMTUwMjA3UFJfTkVXU19VU1BSX19fX19DTjk4MzUy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDE1Jk5ld3NJdGVtSWQ9Q045ODM1MiZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMTUwMjA3UFJfTkVXU19VU1BSX19fX19DTjk4MzUy"/></p>

三诺生物

<p>三诺生物在 2025 年第 61 届欧洲糖尿病研究协会年会上展示了其糖尿病管理解决方案。该公司举办了一场研讨会，邀请国际专家讨论 iCan CGM 的临床表现。新推出的 iCan i6 CGM 系统为用户提供了增强的功能。三诺生物还介绍了其 “A+C” 糖尿病预防与控制生态系统，将非侵入性筛查与 CGM 结合，实现早期风险检测。此次活动强调了三诺生物在糖尿病护理领域对技术创新和全球合作的承诺</p>

<p>, /PRNewswire/ -- The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) was successfully held in Vienna, Austria. During the conference, Sinocare hosted an international industry symposium and an exclusive networking dinner, fully demonstrating the company's professional expertise in diabetes management.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- 第 61 届欧洲糖尿病研究协会年会（EASD 2025）在奥地利维也纳成功举行。在会议期间，三诺生物举办了国际行业研讨会和专属的网络晚宴，充分展示了公司在糖尿病管理方面的专业知识。</p>
</div><p><strong>International Experts Applaud iCan CGM's Exceptional Clinical Performance</strong></p>
<div class="lb-trans"><p><strong>国际专家赞扬 iCan CGM 的卓越临床表现</strong></p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Professor Lori Laffel</p>
<div class="lb-trans"><p>洛里·拉费尔教授</p>
</div><p>On the opening Monday of EASD 2025 in Vienna, Professor Lori Laffel, Dr. Guido Freckmann, and Professor Julia Mader were invited to share their researches collaborated with iCanTM CGM. The symposium highlighted key themes 'Performance, Practicality, and Pediatrics,' and presented promising data from recent German and U.S. studies involving both adult and pediatric populations. Additionally, the session provided insights into initiating CGM systems in real-world settings, featuring expertise from a leading pediatric diabetes center. The discussion also explored the potential impact of diabetes technology on travel and employment opportunities for individuals with diabetes who have a passion for flying.</p>
<div class="lb-trans"><p>在 EASD 2025 开幕的周一，洛里·拉费尔教授、吉多·弗雷克曼博士和朱莉亚·马德尔教授受邀分享与 iCanTM CGM 合作的研究。研讨会强调了 “表现、实用性和儿科” 这几个关键主题，并展示了来自德国和美国的成人及儿童人群的最新研究数据。此外，会议还提供了在实际环境中启动 CGM 系统的见解，展示了来自领先儿科糖尿病中心的专业知识。讨论还探讨了糖尿病技术对热爱飞行的糖尿病患者的旅行和就业机会的潜在影响。</p>
</div><p><strong>Global Launch of iCan i6 CGM: Smarter Monitoring, Elevated Experience</strong></p>
<div class="lb-trans"><p><strong>iCan i6 CGM 全球发布：更智能的监测，提升的体验</strong></p>
</div><p>The next-generation iCan i6 CGM system was the centerpiece of attention in Sinocare's booth. Besides 15-day accuracy and comfortable wear, iCan i6 delivers multiple user experience upgrades: one-step application with a smaller, lighter sensor; 27-language support for global accessibility; built-in altitude compensation algorithm for reliable readings at high elevations; enhanced mobile app integration, enabling a &#34;effortless monitoring and globally accessible&#34; experience.</p>
<div class="lb-trans"><p>下一代 iCan i6 CGM 系统成为三诺生物展位的焦点。除了 15 天的准确性和舒适的佩戴体验，iCan i6 还提供多项用户体验升级：一步应用，配备更小、更轻的传感器；支持 27 种语言，全球可及性；内置高度补偿算法，确保高海拔地区的可靠读数；增强的移动应用集成，实现 “轻松监测和全球可及” 的体验。</p>
</div><p>At the same time, Sinocare's exclusive partner, A.Menarini Diagnostics s.r.l, showcased the co-branded GlucoMen® iCan CGM system at EASD. Menarini highlighted the iCan system's latest features and clinical benefits through an immersive booth experience, drawing strong interest and engagement from medical professionals on-site.</p>
<div class="lb-trans"><p>与此同时，三诺生物的独家合作伙伴 A.Menarini Diagnostics s.r.l 在 EASD 展示了联合品牌的 GlucoMen® iCan CGM 系统。Menarini 通过沉浸式展位体验强调了 iCan 系统的最新功能和临床益处，吸引了现场医疗专业人士的强烈兴趣和参与。</p>
</div><p><strong>From Prevention to Management: Building a Closed-Loop Diabetes Ecosystem</strong></p>
<div class="lb-trans"><p><strong>从预防到管理：构建闭环糖尿病生态系统</strong></p>
</div><p>On September 15, Sinocare hosted a private dinner seminar, unveiling its new &#34;A+C&#34; Diabetes Prevention and Control Ecosystem to key partners. This model integrates AGEscan non-invasive screening with CGM to enable early risk detection and precision intervention. Sinocare also introduced its hospital glucose management solution, which seamlessly connects outpatient and inpatient scenarios, achieving end-to-end digital diabetes management and improving both efficiency and quality of care.</p>
<div class="lb-trans"><p>9 月 15 日，三诺生物举办了一场私人晚宴研讨会，向关键合作伙伴揭示其新的 “A+C” 糖尿病预防与控制生态系统。该模型将 AGEscan 非侵入性筛查与 CGM 结合，以实现早期风险检测和精准干预。三诺生物还介绍了其医院血糖管理解决方案，能够无缝连接门诊和住院场景，实现端到端的数字糖尿病管理，提高效率和护理质量。</p>
</div><p>From cutting-edge CGM clinical research to integrated prevention and hospital management solutions, Sinocare's presence at EASD 2025 strengthened global collaborations with experts and partners, and showcased its deep integration of technological innovation with patient and clinical needs.</p>
<div class="lb-trans"><p>从前沿的 CGM 临床研究到综合的预防和医院管理解决方案，三诺生物在 EASD 2025 的参与加强了与专家和合作伙伴的全球合作，展示了其技术创新与患者和临床需求的深度融合。</p>
</div><p>SOURCE Changsha Sinocare Inc.</p>
<div class="lb-trans"><p>来源：长沙三诺生物股份有限公司</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDE1Jk5ld3NJdGVtSWQ9Q045ODM1MiZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMTUwMjA3UFJfTkVXU19VU1BSX19fX19DTjk4MzUy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN98352&amp;Transmission_Id=202510150207PR_NEWS_USPR_____CN98352&amp;DateId=20251015"/></p>

三诺生物在 EASD 展示其全面的糖尿病管理解决方案